Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Vaccinations01:51

Vaccinations

45.4K
Overview
45.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Development of Immunocompetence01:22

Development of Immunocompetence

466
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
466
Cancer Vaccines01:30

Cancer Vaccines

526
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
526
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

185
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
185

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expediting Drug Development in Japan: A PMDA Perspective.

Clinical pharmacology and therapeutics·2025
Same author

Pib2 is a cysteine sensor involved in TORC1 activation in Saccharomyces cerevisiae.

Cell reports·2023
Same author

Endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of gastric linitis plastica.

DEN open·2022
Same author

Prescription pattern analysis for antibiotics in working-age workers diagnosed with common cold.

Scientific reports·2021
Same author

Isoflurane induces Art2-Rsp5-dependent endocytosis of Bap2 in yeast.

FEBS open bio·2021
Same author

Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.

Internal medicine (Tokyo, Japan)·2021

Related Experiment Video

Updated: Sep 21, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K

[Development and Evaluation about "2nd-wave" COVID-19 Vaccines].

Yasuhiro Araki1

  • 1Pharmaceuticals and Medical Devices Agency.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|June 1, 2022
PubMed
Summary

Clinical trials for COVID-19 vaccines face ethical challenges due to widespread vaccination. Immunogenicity bridging studies may replace placebo trials, requiring new international standards for evaluating future vaccine efficacy and boosters.

Keywords:
coronavirus disease 2019 (COVID-19)regulatory sciencevaccinevaccine efficacy

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K

Related Experiment Videos

Last Updated: Sep 21, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K

Area of Science:

  • Vaccinology
  • Infectious Disease Epidemiology
  • Regulatory Science

Background:

  • Global vaccination campaigns for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are advancing rapidly.
  • Traditional clinical trial designs relying on placebo control groups for efficacy evaluation of coronavirus disease 2019 (COVID-19) vaccines are becoming ethically challenging and logistically difficult.
  • The decreasing number of unvaccinated individuals worldwide complicates the assessment of new vaccine candidates using established methodologies.

Purpose of the Study:

  • To address the challenges in evaluating novel coronavirus disease 2019 (COVID-19) vaccines in the context of widespread public vaccination.
  • To explore alternative approaches for vaccine efficacy assessment when placebo-controlled trials are no longer feasible.
  • To highlight the need for international consensus on future vaccine evaluation strategies, including those for additional immunizations.

Main Methods:

  • Review of current practices in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine clinical trials.
  • Analysis of the impact of increasing global vaccination coverage on trial feasibility and ethical considerations.
  • Discussion of the potential role of immunogenicity bridging studies as an alternative to placebo-controlled efficacy trials.

Main Results:

  • Placebo-controlled trials for coronavirus disease 2019 (COVID-19) vaccines are increasingly difficult to conduct ethically and practically.
  • International regulatory authorities are considering immunogenicity bridging studies as a viable alternative for evaluating new vaccines against approved ones.
  • Future vaccine development and evaluation will require adaptation to changing social contexts and vaccine coverage levels.

Conclusions:

  • The paradigm for evaluating coronavirus disease 2019 (COVID-19) vaccines must evolve beyond traditional placebo-controlled efficacy studies.
  • Immunogenicity bridging studies represent a promising approach for assessing new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.
  • International collaboration and convergence are essential for establishing new standards for vaccine evaluation, particularly for booster doses.